Table 1

Baseline characteristics

 Any admission for HFIncident HFRe-admission for HFAll-cause mortality
Cases (n=14 613)Controls (n=146 130)p ValueCases (n=7212)Controls (n=72 120)p ValueCases (n=1727)Controls (n=17 222)p ValueCases (n=38 248)Controls (n=382 313)p Value
Age at recruitment, years78.0 (8.3)77.9 (8.4)78.3 (8.4)78.2 (8.4)77.9 (8.4)77.9 (8.5)80.2 (9.1)79.9 (9.0)
Sex male7690 (52.6)76 900 (52.6)3577 (49.6)35 770 (49.6)914 (52.9)9102 (52.9)19 215 (50.2)191 983 (50.2)
DPP-4i use (6 months)256 (1.8)2881 (2.0)0.0672135 (1.9)1285 (1.8)0.582037 (2.1)338 (2.0)0.6090306 (0.8)6717 (1.8)<0.0001
DPP-4i use (any)328 (2.2)3636 (2.5)0.0702171 (2.4)1657 (2.3)0.691747 (2.7)470 (2.7)0.9853477 (1.3)8491 (2.2)<0.0001
Previous disorders or treatments
 Ischaemic heart disease (in the past 5 years)3371 (23.1)10 237 (7.0)<0.0001879 (12.2)5492 (7.6)<0.0001281 (16.3)2361 (13.7)0.00344270 (11.2)23 938 (6.3)<0.0001
 Glimepiride or glibenclamide (in the past 6 months)1531 (10.5)16 756 (11.5)0.0003916 (12.7)8144 (11.3)0.0003172 (10.0)1691 (9.8)0.85163428 (9.0)46 327 (12.1)<0.0001
 Insulin (in the past 6 months)5363 (36.7)24 108 (16.5)<0.00012177 (30.2)12 042 (16.7)<0.0001730 (42.3)4459 (25.9)<0.000114 159 (37.0)64 477 (16.9)<0.0001
  • Data are mean (SD) or no. (%).

  • HF, heart failure.